Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
IMNM submitted a Form 144/A notifying the proposed sale of 65,000 shares of Common Stock to be executed through Fidelity Brokerage Services LLC on 04/02/2026 on NASDAQ. The filing lists total value $1,425,084.64 and identifies prior acquisition reasons including stock option exercise (09/19/2024), an option grant (03/23/2023), and a merger payout (10/02/2023).
IMNM submitted a Rule 144 notice regarding proposed sales of common stock. The filing lists 65,000 and $4,723,550.00 alongside an NASDAQ designation and the date 04/02/2026. The excerpt also records earlier transactions tied to specific dates: 09/19/2024 (Stock Option Exercise, 27,620), 03/23/2023 (Option Granted, 17,524) and 10/02/2023 (Merger Payout, 19,856).
The issuer IMNM submitted a Form 144 notice related to proposed sales of Common Stock. The filing lists a proposed sale tied to a stock option exercise of 6,318 shares dated 08/15/2024 and a separate stock option exercise of 3,120 shares dated 03/27/2025. The broker listed is Fidelity Brokerage Services LLC. The filing date shown in the excerpt is 04/02/2026.
Immunome Inc. Chief Scientific Officer Jack Higgins reported a bona fide gift of 6,291 shares of Common Stock. The gift, coded as a disposition, carried a price of $0.00 per share. Following this transfer, he directly holds 31,438 shares of Immunome Common Stock.
The filing also lists indirect holdings of 1,000 shares of Common Stock in each of three custodial accounts for his children, recorded under the Uniform Transfer to Minors Act. Higgins disclaims beneficial ownership of these custodial shares, which are subject to a lockup agreement he entered into on December 15, 2025.
Immunome Inc. President and CEO Clay B. Siegall bought 25,450 shares of Common Stock in an open-market purchase. The transaction occurred on March 27, 2026 at a weighted average price of $19.67 per share, within a price range of $19.63 to $19.70.
Following this purchase, his direct holdings increased to 690,704 shares of Immunome Common Stock.
Immunome Inc: The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment on 01/12/2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries will report holdings separately.
Immunome Inc. director Philip Wagenheim sold shares of Common Stock in two open-market transactions. He sold 36,800 shares on March 20, 2026 at a weighted average price of $20.47 per share and 28,200 shares on March 23, 2026 at a weighted average price of $20.65 per share. After these sales, he directly owns 341,147 shares of Immunome Common Stock.
Immunome Inc. director Jean Jacques Bienaimé reported open-market purchases of the company’s common stock. On March 10, 2026, he bought 1,000 shares at $22.12 per share, followed by another 1,000 shares at $21.55 per share on March 11, 2026. After these total purchases of 2,000 shares, he directly owns 38,415 shares of Immunome common stock.
Immunome, Inc. (IMNM) is an oncology-focused biotechnology company developing antibody‑drug conjugates (ADCs) and radioligand therapies. Its lead program, varegacestat, showed positive topline Phase 3 RINGSIDE results in desmoid tumors, including an 84% reduction in risk of progression or death versus placebo and a 56% objective response rate compared with 9% on placebo. The company plans to submit a new drug application for varegacestat in the second quarter of 2026.
Additional programs include IM‑1021, a ROR1‑targeted ADC in Phase 1 with observed objective responses in B‑cell lymphomas, and IM‑3050, a FAP‑targeted lutetium‑177 radioligand therapy with Phase 1 initiation planned in early 2026. Three preclinical solid‑tumor ADCs (IM‑1617, IM‑1340, IM‑1335) have IND‑enabling work underway with anticipated 2026 submissions. Immunome has expanded its pipeline through transactions with Ayala, Zentalis, BMS and Purdue Research Foundation, and reported an approximate non‑affiliate market value of $728.5 million as of June 30, 2025, with 113,133,199 common shares outstanding as of February 27, 2026.